Get the Stockscreener App
0.1588
0.38%
-0.0006
Pre-market:
.16
0.0012
+0.76%
Medicus Pharma Ltd stock is traded at $0.1588, with a volume of 2.73M.
It is down -0.38% in the last 24 hours and down -38.31% over the past month.
Medicus Pharma Ltd is a clinical-stage, life sciences, biotech company focused on investing in and accelerating clinical development programs of novel and potentially disruptive therapeutic assets. The company has one operating segment.
See More
Previous Close:
$0.1594
Open:
$0.165
24h Volume:
2.73M
Relative Volume:
0.66
Market Cap:
$11.39M
Revenue:
-
Net Income/Loss:
$-28.53M
P/E Ratio:
-0.0892
EPS:
-1.7805
Net Cash Flow:
$-20.10M
1W Performance:
-6.92%
1M Performance:
-38.31%
6M Performance:
-67.53%
1Y Performance:
-93.77%
1-Day Range:
$0.1545
$0.165
1-Week Range:
$0.1545
$0.1759
52-Week Range:
$0.144
$2.78
Medicus Pharma Ltd Stock (MDCX) Company Profile
Name
Medicus Pharma Ltd
Sector
Industry
Phone
610-540-7515
Address
300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN
Compare MDCX vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDCX
Medicus Pharma Ltd
|
0.1588 | 11.39M | 0 | -28.53M | -20.10M | -1.7805 |
LLY
Lilly Eli Co
|
1,181.89 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
270.68 | 652.31B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
265.12 | 468.50B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
147.98 | 365.09B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
143.57 | 272.89B | 54.66B | 13.58B | 16.05B | 7.0171 |
Medicus Pharma Ltd Stock (MDCX) Latest News
Medicus Pharma Ltd. (MDCX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Medicus's Pfizer Deal Was Not a Fire Sale: A Strategic Bet on De-Risked ADC Drug - Streetwise Reports
Medicus Pharma to focus SkinJect development exclusively on Gorlin syndrome patients - Yahoo Finance
Medicus Pharma Optimizes Portfolio Strategy With High-Value Focus - AOL.ca
Medicus Pharma to focus SkinJect development on Gorlin syndrome By Investing.com - Investing.com Australia
Medicus Pharma to focus SkinJect development on Gorlin syndrome - Investing.com
Medicus Pharma Shifts SkinJect Focus to Gorlin Syndrome | MDCX Stock News - Stock Titan
Top Medicus Pharma (MDCX) Competitors 2026 - MarketBeat
Press Release: Medicus Pharma Announces $22 Million Non-Dilutive Financing - Moomoo
Dr. Raza Bokhari Discloses Investment at Medicus Pharma Ltd. with 5.3% Stake - TradingView
Form 8K Medicus Pharma Ltd For: 14 September By Investing.com - Investing.com Australia
Medicus Pharma ends standby equity purchase agreement with Yorkville By Investing.com - Investing.com India
Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI - Yahoo Finance
FDA Clears Medicus SkinJect Study for Gorlin Syndrome - MyChesCo
Inside the deal: How a Montco biotech secured a Pfizer drug candidate - The Business Journals
Form 8K Medicus Pharma Ltd For: 11 September By Investing.com - Investing.com Nigeria
Medicus Pharma officers receive restricted shares in lieu of cash bonuses - Investing.com Nigeria
Medicus Pharma posts phase 2 study results for skin cancer drug By Investing.com - Investing.com Australia
Medicus Pharma posts phase 2 study results for skin cancer drug - Investing.com Nigeria
Medicus Pharma secures Pfizer ADC deal, advances SkinJect and precision oncology strategy - Proactive financial news
Medicus Pharma Identifies 200 µg SkinJect Patch as Lead Development Dose After Phase 2 Study - Yahoo Finance
Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment - Proactive financial news
Conshohocken's Medicus Pharma Picks Up a Discarded Pfizer Cancer Drug in a Deal Worth More Than $1 Billion - BioBuzz
Medicus Pharma Advances Transformation into a Precision Oncology-Led Biotechnology Company - BioBuzz
Medicus Pharma Ltd. Posts Abridged Phase 2 Clinical Study Report for SkinJect® SKNJCT-003, Advances Gorlin Syndrome Development Plan - Quiver Quantitative
FDA authorizes the next study of a skin cancer patch - Stock Titan
MDCX Stock Price, Quote & Chart - ChartMill
Medicus Pharma (MDCX) grants COO 735K shares and options - Stock Titan
Medicus Pharma (NASDAQ: MDCX) awards stock and options to its chief medical officer - Stock Titan
Medicus Pharma (MDCX) hands CSO 588K shares and 100K options - Stock Titan
Medicus Pharma (MDCX) CEO adds millions of shares and options in 2026 grant - Stock Titan
CFO adds Medicus Pharma (MDCX) stock and options - Stock Titan
Medicus Pharma reorients around new cancer drug candidate, sharpens focus for other programs - Proactive financial news
Medicus Pharma Prioritises CD228V Oncology Programme in Development Strategy - Yahoo Finance
Medicus Pharma shifts focus to precision oncology with CD228V By Investing.com - Investing.com Nigeria
Medicus Pharma shifts focus to precision oncology with CD228V - Investing.com
Medicus Pharma Ltd. Repositions as Precision Oncology-Led Biotech, Prioritizes CD228V, SkinJect and Teverelix Programs - Quiver Quantitative
New to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast (NASDAQ:CAST), Stardust Power (NASDAQ:SDST), Lost Soldier Oil and Gas, Virtuix Holdings (NASDAQ:VTIX), and Medi - ACCESS Newswire
Price to sales forward of Medicus Pharma Ltd. – NASDAQ:MDCXW - TradingView
MDCX Should I Buy - Intellectia AI
Medicus Pharma Ltd. Common Stock (NASDAQ: MDCX) Stock Price, News & Analysis - Kalkine
Pfizer hands former Seagen ADC to Medicus in USD 1b-plus deal - AllSci
Pfizer Licenses Discontinued Cancer Drug to Medicus Pharma in Deal Valued Over $1 Billion - finance.biggo.com
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion - Benzinga
Medicus Pharma Secures Global Rights to Pfizer’s CD228V with $12M Initial Payment and $15M Commitment - kalkinemedia.com
$Medicus Pharma (MDCX.US)$ - Moomoo
Medicus Pharma inks deal with Pfizer to advance clinical-stage ADC - The Pharma Letter
Pfizer, Medicus ink licensing deal worth up to $1B (PFE:NYSE) - Seeking Alpha
Medicus Pharma Signs Potential $1B Deal to License Pfizer’s Cancer Drug CD228V - Minichart
Medicus Pharma Ltd. Submits to the FDA Phase 2 IND Clinical Protocol to Non-Invasively Treat Basal Cell Carcinoma of the Skin - TMX Newsfile
Medicus Pharma Warrant (MDCXW) Holds Steady at $0.33 as Trading Range TightensRVOL Breakout - vinanet.vn
Medicus Pharma Ltd Stock (MDCX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.82%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):